Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia

Phase 1

Completed

• Conditions: Myelodysplastic Syndromes and Leukemia, Myeloid, Acute
• Interventions: Drug: Arsenic Trioxide; Drug: Decitabine

• Registration Number: NCT00671697
• Lead Sponsor: Washington University School of Medicine

Brief Summary

This study is designed to test the combination of decitabine, arsenic trioxide and ascorbic acid in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia

Detailed Description

Myelodysplastic syndromes (MDS) are hematological disorders characterized by ineffective hematopoiesis. DNA hypomethylating agents such as decitabine have been shown to have activity in this disorder by reversing the epigenetic mechanism of gene silencing.

Acute Myeloid Leukemia (AML) is a hematological disorder characterized by ineffective hematopoiesis and malignant expansion of clonal myeloid cells. In elderly patients (≥ 60 years old), MDS commonly precedes the diagnosis of AML. Standard therapy for AML consists of cytotoxic chemotherapy and is often followed with allogeneic stem cell transplantation. Unfortunately, elderly patients are often unable to tolerate such aggressive therapy.

Arsenic has also shown activity in patients with MDS and AML though modulation of apoptosis via increased oxidative stress. In preclinical modes, arsenic activity is related to the production of radical oxygen species that damage mitochondria. Cellular glutathione acts as a cellular antioxidant and can be depleted with the vitamin ascorbic acid which increases intracellular oxidative stress and sensitivity to arsenic trioxide induced apoptosis.

We are studying the combination of decitabine, arsenic trioxide and ascorbic acid, two primary agents and one vitamin all with different mechanisms of action in order to improve the response rate in patients with MDS and AML. This is an open-label, single-arm, single-center, dose escalation Phase I trial of decitabine, arsenic trioxide and ascorbic acid in patients with MDS, either de novo or secondary, fitting any of the FAB classifications and AML.

Study Timeline

• Study Start: 2008-05
• Study First Submitted: 2008-05-01
• Study First Submitted QC: 2008-05-01
• Study First Posted: 2008-05-05
• Primary Completion: 2010-01
• Study Completion: 2011-05
• Status Verified: 2013-05
• Last Update Submitted: 2013-05-31
• Last Update Posted: 2013-06-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 13

Inclusion Criteria

1. MDS (either de novo or secondary) fitting any of the FAB classifications or AML defined by FAB classification criteria. Patients with < 5% bone marrow blasts must also meet one of the following criteria:

   1. Symptomatic anemia with either hemoglobin <10.0 g/dL or requiring red blood cell (RBC) transfusion
   2. Thrombocytopenia with a history of two or more platelet counts < 50,000 / µL or a significant hemorrhage requiring platelet transfusions, or
   3. Neutropenia with two or more absolute neutrophil counts < 1,000 /µL.

   AML patients must also have a WBC < 10,000µL and meet one of the following two criteria:

   1. Age greater than or equal to 60 years
   2. Relapsed AML and are not a candidate for cytotoxic chemotherapy.

2. ECOG performance status of 0-2.

3. Must give written informed consent indicating their awareness of the investigational nature of this study and its potential hazards.

4. Adequate renal and hepatic function (creatinine < 1.5x institutional upper limit of normal, total bilirubin ≤ 1.5x institutional upper limit of normal, AST and ALT ≤ 2x institutional upper limit of normal).

5. Serum potassium > 4.0 mEq/L, serum magnesium > 1.8 mg/dL.

6. Life expectancy of at least 16 weeks.

7. Women of childbearing age must have a negative serum pregnancy test prior to initiating therapy.

8. Sexually active women of childbearing potential must use effective birth control during the trial and for at least two months following the trial.

9. Men must be willing to avoid fathering a new child while receiving therapy with decitabine.

10. Greater than or equal to 18 years, no upper age limit

11. Individuals who are candidates for hematopoietic stem cell transplantation and who meet all other study criteria may participate in the study and receive intravenous decitabine in combination with arsenic trioxide and Ascorbic acid as a treatment prior to transplantation.

Exclusion Criteria

1. Known central nervous system (CNS) leukemia.
2. Previously received greater than or equal to 5 cycles of azacitidine (Vidaza®, Pharmion Corp., Boulder, CO) or decitabine (Dacogen®, MGI Pharma Inc. Bloomington, MN).
3. QTc > 460 msec.
4. Known or suspected hypersensitivity to decitabine, arsenic or ascorbic acid.
5. Receiving any other investigational agents within 30 days of first dose of study drug.
6. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, congestive heart failure of NYHA class 3 or 4, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situation that would limit compliance with study requirements.
7. Known positive serology for HIV.
8. Had radiotherapy within 14 days prior to study enrollment.
9. Known presence of hepatic tumors.
10. < 18 years of age
11. Exclude women who are pregnant or breast feeding.
12. Known history of glucose-6-phosphate deficiency (G6PD).
13. Currently taking a Class Ia or Class III antiarrhythmic or other medication causally associated with prolonging QTc.
14. Use of aspirin with platelet counts < 50,000/µl.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Dose Level 2 Arsenic Trioxide & Decitabine	Arsenic Trioxide	Arsenic trioxide loading dose of 0.2 mg/kg/day IV x 5 days followed by weekly doses of 0.2 mg/kg IV for 15 additional weeks. Decitabine 20 mg/m2 IV every day on days 1-5 of a 4 weeks cycle for 4 cycles.
Dose Level 2 Arsenic Trioxide & Decitabine	Decitabine	Arsenic trioxide loading dose of 0.2 mg/kg/day IV x 5 days followed by weekly doses of 0.2 mg/kg IV for 15 additional weeks. Decitabine 20 mg/m2 IV every day on days 1-5 of a 4 weeks cycle for 4 cycles.
Dose Level 3 Arsenic Trioxide & Decitabine	Arsenic Trioxide	Arsenic trioxide loading dose of 0.3 mg/kg/day IV x 5 days followed by weekly doses of 0.3 mg/kg IV for 15 additional weeks. Decitabine 20 mg/m2 IV every day on days 1-5 of a 4 weeks cycle for 4 cycles.
Dose Level 3 Arsenic Trioxide & Decitabine	Decitabine	Arsenic trioxide loading dose of 0.3 mg/kg/day IV x 5 days followed by weekly doses of 0.3 mg/kg IV for 15 additional weeks. Decitabine 20 mg/m2 IV every day on days 1-5 of a 4 weeks cycle for 4 cycles.
Dose Level 1 Arsenic Trioxide & Decitabine	Arsenic Trioxide	Arsenic trioxide loading dose of 0.1 mg/kg/day IV x 5 days followed by weekly doses of 0.1 mg/kg IV for 15 additional weeks. Decitabine 20 mg/m2 IV every day on days 1-5 of a 4 weeks cycle for 4 cycles.
Dose Level 1 Arsenic Trioxide & Decitabine	Decitabine	Arsenic trioxide loading dose of 0.1 mg/kg/day IV x 5 days followed by weekly doses of 0.1 mg/kg IV for 15 additional weeks. Decitabine 20 mg/m2 IV every day on days 1-5 of a 4 weeks cycle for 4 cycles.

Primary Outcome Measures

Name	Time	Method
To define the maximum tolerated dose and dose-limiting toxicities during four cycles of combination decitabine, arsenic trioxide and ascorbic acid in patients with myelodysplastic syndromes (MDS) previously untreated with hypomethylating agents.	4 months after the final patient on the final cohort starts treatment

Secondary Outcome Measures

Name	Time	Method
To estimate the rate of complete remission (CR) and partial remission (PR) after four cycles of therapy in patients with MDS.	After 4 cycles of treatment
To determine the rate of hematologic improvement	Weekly through the end of treatment
To determine the rate of transfusion independence	Through completion of treatment
To determine the time to disease progression to AML	Every 4 weeks during treatment and then every 2 months for 2 years after the first dose of study drug
To determine the rate of cytogenetic response	After every 2 cycles
To determine the rate of overall survival	Every 4 weeks during treatment and then every 2 months for 2 years after the first dose of study drug
To determine changes in bone marrow vascular density	At baseline, end of cycle 2, end of cycle 4, and end of study
To determine changes in angiogenic mRNA expression.	Baseline, end of cycle 2, end of cycle 4, and end of study

Trial Locations

Locations (1)

Washington University; 🇺🇸 St. Louis, Missouri, United States